Morgan Stanley
BNR

Morgan Stanley’s Burning Rock Biotech BNR Stock Holding History

Morgan Stanley’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Buy
43,594
+28,322
+185% +$401K ﹤0.01% 5693
2026
Q1 		$246K Buy
15,272
+3,432
+29% +$89.9K ﹤0.01% 5791
2025
Q4 		$239K Sell
11,840
-10,427
-47% -$152K ﹤0.01% 5860
2025
Q3 		$193K Buy
22,267
+4,060
+22% +$29.1K ﹤0.01% 5910
2025
Q2 		$57.5K Buy
18,207
+7,481
+70% +$23.2K ﹤0.01% 6311
2025
Q1 		$48.3K Hold
10,726
– – ﹤0.01% 6276
2024
Q4 		$72.4K Buy
10,726
+300
+3% +$1.38K ﹤0.01% 6176
2024
Q3 		$34K Sell
10,426
-5,557
-35% -$30.7K ﹤0.01% 6330
2024
Q2 		$103K Sell
15,983
-6,405
-29% -$48.8K ﹤0.01% 5953
2024
Q1 		$163K Sell
22,388
-9,593
-30% -$80.1K ﹤0.01% 5792
2023
Q4 		$297K Sell
31,981
-7
-0% -$64 ﹤0.01% 5550
2023
Q3 		$310K Sell
31,988
-31,385
-50% -$490K ﹤0.01% 5381
2023
Q2 		$1.36M Sell
63,373
-13,992
-18% -$371K ﹤0.01% 4646
2023
Q1 		$2.17M Sell
77,365
-13,836
-15% -$415K ﹤0.01% 4415
2022
Q4 		$2.05M Sell
91,201
-298
-0.3% -$6.8K ﹤0.01% 4445
2022
Q3 		$2.19M Sell
91,499
-5,921
-6% -$191K ﹤0.01% 4365
2022
Q2 		$2.83M Buy
97,420
+8,839
+10% +$395K ﹤0.01% 4261
2022
Q1 		$8.23M Buy
88,581
+36,109
+69% +$3.14M ﹤0.01% 3136
2021
Q4 		$5M Buy
52,472
+5,708
+12% +$782K ﹤0.01% 3718
2021
Q3 		$8.36M Buy
46,764
+31,065
+198% +$6.91M ﹤0.01% 3103
2021
Q2 		$4.63M Buy
15,699
+15,579
+12,983% +$4.61M ﹤0.01% 3863
2021
Q1 		$32K Sell
120
-634
-84% -$193K ﹤0.01% 6553
2020
Q4 		$174K Buy
754
+393
+109% +$106K ﹤0.01% 5660
2020
Q3 		$90K Buy
361
+280
+346% +$66.4K ﹤0.01% 5472
2020
Q2 		$22K Buy
+81
New +$22.2K ﹤0.01% 5979

Other funds holding BNR

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return

Morgan Stanley's BNR Position: Q2 2026 in Review

Morgan Stanley increased its Burning Rock Biotech (BNR) stake by 185% in Q2 2026, buying an estimated $401K and bringing the position to 43,594 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #5693.

Morgan Stanley first reported a position in BNR in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.36M in Q3 2021. 17 funds tracked by Wall St. Rank hold BNR as of Q2 2026.

  • Morgan Stanley held 43,594 shares of Burning Rock Biotech worth $365K as of Q2 2026.
  • Morgan Stanley bought 28,322 Burning Rock Biotech shares in Q2 2026, an estimated $401K.
  • Burning Rock Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5693 holding.
  • Morgan Stanley first reported a position in Burning Rock Biotech in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Burning Rock Biotech position peaked at $8.36M in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.